Romania has once again proved fertile ground for Swissray, which is selling the Romanian government 30 ddRChest-Systems for more than $7 million, in addition to the 32 ddRMulti-Systems delivered earlier this year for $13.8 million.Swissray reported its
Romania has once again proved fertile ground for Swissray, which is selling the Romanian government 30 ddRChest-Systems for more than $7 million, in addition to the 32 ddRMulti-Systems delivered earlier this year for $13.8 million.
Swissray reported its first-ever positive cash flow from operating activities (SCAN, 10/11/00). The Switzerland-based company said it has sold or contracted for more than 100 ddR systems worldwide. The company hopes to surpass this figure in 2001.
Swissray was delisted from the NASDAQ stock exchange in 1998 after its stock steadily declined to a per-share price below $1. With sales now climbing, the company hopes to be relisted soon.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.